Compare Eli Lilly And Co (LLY) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Wynn Resorts, Limited — how do they compare? Eli Lilly And Co trades at $1,177 (market cap $1.04T), while Wynn Resorts, Limited trades at $75.32 (market cap $7.75B). The key difference: Eli Lilly And Co is far larger — about 134.2× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays the higher dividend (1.33%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Wynn Resorts, Limited for 76 Days on average.
| LLY | WYNN | |
|---|---|---|
Market Cap | $1.04T | $7.75B |
Volume | 3,064,878 | 2,243,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $133.09 |
52-Week Low | $799.57 | $74.97 |
Typical Hold Time | 93 Days | 76 Days |
Enterprise Value | $1.09T | $17.99B |
Dividend Yield | 0.59% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Wynn Resorts (WYNN) trades at $75.24, up 0.36% with bearish technical signals from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but showing margin pressure in U.S. operations. Revenue growth is driven by Macau strength, while significant capital expenditures for new projects in the UAE create cash flow challenges. Analyst consensus remains strongly bullish with a $132.36 price target despite recent earnings volatility and high debt levels.
Investment outlook balances strong Macau recovery against rising capex risks. The stock offers 76% upside to consensus target but faces execution risks on new projects and persistent debt burden. Near-term catalysts include Q3 earnings and UAE project developments, while margin compression and economic sensitivity remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
